• Nie Znaleziono Wyników



Academic year: 2022


Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Dear Colleagues,

The 53rd European Association for the Study of Diabetes Annual Meeting (EASD 2017) was held on 11–15 September 2017 in Lisbon, Portugal. It was attended by around 15,000 physicians from around the world who had the opportunity to discuss and exchange experiences on key issues of contemporary diabetes. Many interesting reports presented during the Congress discussed, among others, epidemiology, new possibilities associated with molecular biology in the practical aspect of translation of basic sciences into da- ily clinical practice, the problem of obesity and related insulin resistance, vascular complications of diabetes and new therapies, especially in terms of cardiovascular risk. Due to the progressive nature of the disease and the gradual deterioration of pancreatic b-cell function, glycaemic control still remains difficult, which stimu- lates the search for new directions and optimal thera- pies. And it is the results of recent studies assessing new therapies, their effects on the optimization of metabolic control, the risk of hypoglycaemia and the primary and secondary prevention of cardiovascular complications, but also the cerebrovascular and renal protection, that raised the most interest and hope for the change of treatment philosophy. However, after previous pro- mising data from the LEADER and SUSTAIN-6 studies, the results of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) with another GLP-1 agonist, exenatide, administered once a week were slightly disappointing. The study included 14,752 type 2 dia- betic patients with median disease duration of about 12 years, of which 73.1% had a positive CVD history.

It has been shown that exenatide does not increase cardiovascular risk, the risk of hospitalization due to heart failure or the risk of inflammation or pancreatic cancer. However, no significant reduction was found in primary endpoint defined as cardiovascular death, myocardial infarction, or non-fatal stroke (11.4%

vs. 12.2%; HR = 0.91, p = 0.06) and the observed reduction in total mortality was not associated with a reduction in cardiovascular mortality. Thus, the que- stion remains whether the GLP1 agonists differ in their ability of signal transmission and the biological effects

exerted. Another interesting direction of research is the use of drugs that affect sodium-glucose cotransport, in combination with insulin, in type 1 diabetes. In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with sotagliflozin, a SGLT1/SGLT2 inhibitor, attention was paid to the potential benefits, but also threats, of such therapy associated with increased risk of ketoacidosis. Primary endpoint was HbA1c < 7.0%

after 24 weeks of follow-up without severe episodes of hypoglycaemia or diabetic ketoacidosis (DKA). This goal was achieved by significantly more patients in the sota- gliflozin group — 29.6% vs. 15.8%, p < 0.001. Similar percentages of documented episodes of hypoglycaemia were observed in both groups, but the incidence of severe hypoglycaemia was significantly lower in the sotagliflozin group than in the control group (11.8%

vs. 15.4% per patient-year of observation). Unfortuna- tely, in the sotagliflozin group there were more cases of DKA (8.6% vs. 2.4%). The difference was higher among patients using personal insulin pumps compared to those on multiple injection regimen, suggesting that, at least in part, the cause was rather the device failure than the study drug itself. More encouraging, at this stage of research, were the results of observation in type 1 diabetes patients receiving dapagliflozin — the DEPICT-1 (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) study. In this study, the addition of dapagliflozin, regardless of the dose applied (5 or 10 mg), to insulin, when failed to be sufficiently effective, resulted in a significant reduction in HbA1c [5 mg vs. placebo — 0.42% (p < .0001); 10 mg vs. placebo — 0.45% (p < .0001)], weight loss [5 mg vs. placebo — 2.96% (p < .0001); 10 mg vs. placebo

— 3.72% (p < .0001)] and a decrease in the daily insulin requirement [5 mg vs. placebo — 8.8% (p < .0001);

10 mg vs. placebo — 13.2% (p < .0001)]. The percen- tage of hypoglycaemic episodes and adverse events, in- cluding DKA, was comparable between groups. Despite such promising results, the question remains whether the observed weight loss would be a desirable outcome


in type 1 diabetic patients with normal BMI, as well as a decrease in systolic BP in patients with low baseline values and, finally, if the reduction in insulin dose in a group of patients with low initial insulin requirement would be as safe as in the study. It is also important to precisely identify patients with type 1 diabetes who are particularly exposed to ketosis, when using the SGLT2 inhibitor in combination with insulin.

The current issue of “Clinical Diabetology”, like the previous one, also includes interesting reports on diagnostic and therapeutic options that, I hope, will support your daily practice. I would like highlight again that medicine is still an art that often does not know easy ways or fully predictable solutions, and that diabetes treatment should always be of benefit to the patient.


Prof. Janusz Gumprecht


Powiązane dokumenty

Zgodnie z rekomendacjami polskich i między- narodowych towarzystw diabetologicznych [6, 14], jeżeli pod wpływem leczenia metforminą nie uzy- skuje się wyrównania metabolicznego

Podstawowym celem leczenia cukrzycy jest osiągnię- cie normoglikemii lub stanu przybliżonego do nor- moglikemii. Jest to istotne ze względu na fakt, że w badaniu DCCT i UKPDS

In children, especially girls, with higher HbA1c values, the return to intensive insulin therapy using multiple injections may help to improve the control of

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

The Diabetes Control and Complication Trial (DCCT) has shown the relationship between better glycaemic control in patients treated with intensive insulin therapy and lower risk

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to